Novartis Names Andre Wyss To Run Its North American And U.S. Pharma Business
This article was originally published in The Pink Sheet Daily
Executive Summary
The 25-year Novartis veteran succeeds Ludwig Hantson, who was simultaneously named as corporate vice president at Baxter International.
You may also be interested in...
Novartis Reorganizes Its US Pharma Unit, Replacing CEO And Slashing 250 Jobs
The drug maker creates four business units, including primary care, which remains "critically important" to future growth.
No Sales Model Left Behind: Novartis Joins Firms In Changing Market Focus
Novartis is joining the horde of pharmaceutical companies that are revamping their sales and marketing organizations in response to a U.S. market that is rapidly changing, at varying paces in different regions
The John Green Effect: Will Industry Be Influenced Again?
Drug and device makers regularly use media to sway consumers. But some advocacy groups recently turned the tables by using social media to sway industry.